about
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancersDouble-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cellsFrequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcomeGenomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.Prognostic role of CIP2A expression in serous ovarian cancerEpigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancerMicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer.Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas.CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinomaEzrin immunoreactivity in relation to survival in serous ovarian carcinoma patientsDistinct subtypes of serous ovarian carcinoma identified by p53 determinationCombination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinomaCytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinomaDecreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinomaGene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
P50
Q21562662-3419397B-CDC8-4892-A90B-E95E2083331CQ24598592-010760F1-891A-41AF-82BF-79BB23BF8500Q35032772-B94F4B76-A25C-459A-9A60-7C5356BE261AQ35032994-7DD2D496-8686-4312-8748-561C2926D958Q35263210-07441B0C-D44D-4E5D-8FD6-3333FC6252CCQ36213561-917AA148-F499-4BF5-B5F3-A2356EDBE052Q36657641-5377E020-F9E6-476D-B8F3-60F69ACC7628Q37388413-6CF43574-48EC-4476-A5E9-1E05FB965BDCQ43198996-0EAA4483-F537-4FD5-BB8C-BB2EEFDB5965Q50742113-5BE0B125-148F-46F6-BBEC-D526CF0A9979Q51647531-6BAFFAA8-4B53-406C-92EF-129858D71DC0Q54457600-8BEDAB90-E11F-43E6-989B-4843CCE8A86AQ62725074-330F6BAD-5AB6-475B-A564-ED3DCC9CC146Q73739370-6E7D94D4-06EB-42AA-B516-B15E203DFB36Q79366828-59FBA50F-40AE-48DE-850F-5B78AA19D9F4Q80245094-8BA79E93-B6CC-4318-ACEC-80B05DD00C14Q81124588-15F6ABF6-D875-47E7-B503-DC0FB3622508Q82294671-6EBA20ED-3784-47B6-9DAE-EC5924F3BB62Q83139511-8F9D3530-AB2F-4C56-8CDE-C1C9F49A815C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Heini Lassus
@ast
Heini Lassus
@en
Heini Lassus
@es
Heini Lassus
@nl
Heini Lassus
@sl
type
label
Heini Lassus
@ast
Heini Lassus
@en
Heini Lassus
@es
Heini Lassus
@nl
Heini Lassus
@sl
prefLabel
Heini Lassus
@ast
Heini Lassus
@en
Heini Lassus
@es
Heini Lassus
@nl
Heini Lassus
@sl
P106
P31
P496
0000-0003-0598-5147